Related references
Note: Only part of the references are listed.Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer
Bingnan Zhang et al.
BRITISH JOURNAL OF CANCER (2022)
Structural, molecular, and functional insights into Schlafen proteins
Ukhyun Jo et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2022)
Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features
Changyu Zhu et al.
JOURNAL OF HEPATOLOGY (2021)
Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans
Haichuan Wang et al.
HEPATOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
Ukhyun Jo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243
Yasuhisa Murai et al.
CANCER RESEARCH (2021)
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2021)
RBM10: Structure, functions, and associated diseases
Akira Inoue
GENE (2021)
Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
Victoria Tserpeli et al.
CANCERS (2021)
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
Bingnan Zhang et al.
BRITISH JOURNAL OF CANCER (2021)
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
Claudia Winkler et al.
JCI INSIGHT (2021)
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
Yao-Hui Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
Liang-qing Dong et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway
Chenhao Zhou et al.
THERANOSTICS (2020)
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
Ying Zhu et al.
GUT (2019)
SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
Riccardo Mezzadra et al.
PLOS ONE (2019)
Macrophages and hepatocellular carcinoma
Zhiqiang Tian et al.
CELL AND BIOSCIENCE (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
RNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy
Denise Lau et al.
TRENDS IN CANCER (2019)
Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
David Linehan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Junko Murai et al.
MOLECULAR CELL (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
Chenhao Zhou et al.
CANCER MEDICINE (2018)
Notch Signaling in the Tumor Microenvironment
Olivier Meurette et al.
CANCER CELL (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Integrin CD11b activation drives anti-tumor innate immunity
Michael C. Schmid et al.
NATURE COMMUNICATIONS (2018)
The Schlafen family: complex roles in different cell types and virus replication
Furao Liu et al.
CELL BIOLOGY INTERNATIONAL (2018)
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
Xiaoguang Li et al.
GUT (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
Jun Chen et al.
NATURE (2017)
An RRM-ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion
Katherine M. Collins et al.
NUCLEIC ACIDS RESEARCH (2017)
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer
Wenbo Yao et al.
EBIOMEDICINE (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
F-box protein FBXW7 inhibits-cancer metastasis in a non-cell-autonomous manner
Kanae Yumimoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen K. Sandhu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
Martin Franz Sprinzl et al.
HEPATOLOGY (2013)
RBM5, 6, and 10 Differentially Regulate NUMB Alternative Splicing to Control Cancer Cell Proliferation
Elias G. Bechara et al.
MOLECULAR CELL (2013)
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11
Manqing Li et al.
NATURE (2012)
CURRENT CONCEPTS Hepatocellular Carcinoma
Hashem B. El-Serag
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Share Paper
